Clinical trial
Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of…
NCT00081510 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00081510 |
|---|---|
| Title | Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480) |
| Official title | A Randomized Double-Blind Phase-2 Study of Anastrozole Plus Lonafarnib (SCH 66336) or Anastrozole Plus Placebo for the Treatment of Subjects With Advanced Breast Cancer |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Lonafarnib, Placebo, anastrozole |
| Enrollment | 110 |
| Start date | Dec 1, 2003 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Apr 16, 2004 |
| Last update posted | Apr 15, 2015 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: